Cargando…

SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans

SCO-267 is a full agonist of the free fatty acid receptor 1 (GPR40), which regulates the secretion of islet and gut hormones. In this phase 1 study, we aimed to evaluate the clinical profile of single and multiple once-daily oral administration of SCO-267 in healthy adults and patients with diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishizaki, Harunobu, Matsuoka, Osamu, Kagawa, Tomoya, Kobayashi, Akihiro, Watanabe, Masanori, Moritoh, Yusuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2021
Materias:	Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571351/ https://www.ncbi.nlm.nih.gov/pubmed/34321316 http://dx.doi.org/10.2337/db21-0451

Ejemplares similares

An Exploratory Randomized Trial of SCO-792, an Enteropeptidase Inhibitor, in Patients With Type 2 Diabetes and Albuminuria
por: Kagawa, Tomoya, et al.
Publicado: (2022)

Enteropeptidase inhibitor SCO-792 effectively prevents kidney function decline and fibrosis in a rat model of chronic kidney disease
por: Katayama, Yuko, et al.
Publicado: (2020)

GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve
por: Ueno, Hikaru, et al.
Publicado: (2019)

SCO‐792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice
por: Yashiro, Hiroaki, et al.
Publicado: (2019)

Discovery and characterization of a small‐molecule enteropeptidase inhibitor, SCO‐792
por: Sasaki, Masako, et al.
Publicado: (2019)

Identification of Crocetin as a Dual Agonist of GPR40 and GPR120 Responsible for the Antidiabetic Effect of Saffron
por: Zhao, Xiaodi, et al.
Publicado: (2023)

A novel GPR40 agonist, CNX-011-67, suppresses glucagon secretion in pancreatic islets under chronic glucolipotoxic conditions in vitro
por: Verma, Mahesh Kumar, et al.
Publicado: (2014)

Predicting GPR40 Agonists with A Deep Learning‐Based Ensemble Model
por: Yang, Jiamin, et al.
Publicado: (2023)

Selective Small-Molecule Agonists of G Protein–Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice
por: Tan, Carina P., et al.
Publicado: (2008)

CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients
por: Sunil, Venkategowda, et al.
Publicado: (2014)

A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in Rodents
por: Luo, Jian, et al.
Publicado: (2012)

Fasiglifam (TAK-875), a G Protein-Coupled Receptor 40 (GPR40) Agonist, May Induce Hepatotoxicity through Reactive Oxygen Species Generation in a GPR40-Dependent Manner
por: Kim, MinJeong, et al.
Publicado: (2018)

Euromech Colloquium 267
Publicado: (1990)

GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent
por: Pachanski, Michele J., et al.
Publicado: (2017)

Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey
por: Bazydlo-Guzenda, Katarzyna, et al.
Publicado: (2021)

Ginseng Gintonin Contains Ligands for GPR40 and GPR55
por: Cho, Yeon-Jin, et al.
Publicado: (2020)

Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40
por: Oflazoglu, E, et al.
Publicado: (2009)

Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long‐Acting β (2)‐Agonists and Inhaled Corticosteroids: The OUTPUL Study
por: Ferroni, Eliana, et al.
Publicado: (2016)

SAT-267 Predictors of Poor Glycemic Control in Adolescents with Type 1 Diabetes Transitioning to Adult Care
por: Al-Yahyawi, Naseem, et al.
Publicado: (2019)

T40. GPR52 AGONISTS REPRESENT A NOVEL APPROACH TO TREAT UNMET MEDICAL NEED IN SCHIZOPHRENIA
por: Grottick, Andrew J, et al.
Publicado: (2018)

Effect of Intensive Glycemic and Blood Pressure Control on QT Prolongation in Diabetes: The ACCORD Trial
por: Singleton, Matthew J., et al.
Publicado: (2020)

Deletion of GPR40 Impairs Glucose-Induced Insulin Secretion In Vivo in Mice Without Affecting Intracellular Fuel Metabolism in Islets
por: Alquier, Thierry, et al.
Publicado: (2009)

A Fully Human, Allosteric Monoclonal Antibody That Activates the Insulin Receptor and Improves Glycemic Control
por: Bhaskar, Vinay, et al.
Publicado: (2012)

GPR40 agonist ameliorates liver X receptor-induced lipid accumulation in liver by activating AMPK pathway
por: Li, Meng, et al.
Publicado: (2016)

Phenotypic Type 2 Diabetes in Obese Youth: Insulin Sensitivity and Secretion in Islet Cell Antibody–Negative Versus –Positive Patients
por: Tfayli, Hala, et al.
Publicado: (2009)

GPR40: Good Cop, Bad Cop?
por: Alquier, Thierry, et al.
Publicado: (2009)

GPR40 Modulators: New Kid on the Block
por: Basu, Ananda, et al.
Publicado: (2013)

Identification of a Small Molecular Insulin Receptor Agonist With Potent Antidiabetes Activity
por: Qiang, Guifen, et al.
Publicado: (2014)

Multiple tyrosine metabolites are GPR35 agonists
por: Deng, Huayun, et al.
Publicado: (2012)

Common Variants at 10 Genomic Loci Influence Hemoglobin A(1C) Levels via Glycemic and Nonglycemic Pathways
por: Soranzo, Nicole, et al.
Publicado: (2010)

Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency
por: Krasavin, Mikhail, et al.
Publicado: (2016)

The GPR40 Agonist GW9508 Enhances Neutrophil Function to Aid Bacterial Clearance During E. coli Infections
por: Souza, Patricia R., et al.
Publicado: (2020)

Insights into the molecular mechanism of positive cooperativity between partial agonist MK-8666 and full allosteric agonist AP8 of hGPR40 by Gaussian accelerated molecular dynamics (GaMD) simulations
por: An, Xiaoli, et al.
Publicado: (2021)

Polymorphic Transformation and Magnetic Properties of Rapidly Solidified Fe(26.7)Co(26.7)Ni(26.7)Si(8.9)B(11.0) High-Entropy Alloys
por: Zhang, Zequn, et al.
Publicado: (2019)

The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo
por: Huan, Yi, et al.
Publicado: (2017)

Constitutive androstane receptor agonist CITCO inhibits growth and expansion of brain tumour stem cells
por: Chakraborty, S, et al.
Publicado: (2011)

Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes
por: Hernandez-Perez, Marimar, et al.
Publicado: (2017)

Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma
por: Kang, Zhigang, et al.
Publicado: (2015)

AMG 837: A Novel GPR40/FFA1 Agonist that Enhances Insulin Secretion and Lowers Glucose Levels in Rodents
por: Lin, Daniel C.-H., et al.
Publicado: (2011)

Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus
por: Naik, H, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vnarg7cpulfpo7aat9h9iebhtr